Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy.
Dima D, Abdallah AO, Davis JA, Awada H, Goel U, Rashid A, DeJarnette S, Anwer F, Shune L, Raza S, Mahmoudjafari Z, Williams L, Faiman B, McGuirk JP, Sauter CS, Ahmed N, Khouri J, Hashmi H.
Dima D, et al. Among authors: rashid a.
Blood Cancer J. 2024 May 31;14(1):90. doi: 10.1038/s41408-024-01068-w.
Blood Cancer J. 2024.
PMID: 38821914
Free PMC article.